NorthView Acquisition Corporation (NVAC) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
207 WEST 25TH ST, 9TH FLOOR NEW YORK, NY 10001 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 3841 - Surgical and Medical Instruments and Apparatus (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 5 | 193 | 741 | |||
| Cash and cash equivalents | 5 | 193 | 741 | |||
| Receivables | 25 | |||||
| Prepaid expense | ||||||
| Asset, held-in-trust | ||||||
| Other undisclosed current assets | 1,572 | 318 | 332 | |||
| Total current assets: | 1,576 | 512 | 1,099 | |||
| Noncurrent Assets | ||||||
| Prepaid expense | 308 | |||||
| Asset, held-in-trust | 9,308 | 194,225 | 191,654 | |||
| Total noncurrent assets: | 9,308 | 194,225 | 191,962 | |||
| TOTAL ASSETS: | 10,885 | 194,736 | 193,061 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 449 | 911 | 105 | |||
| Accrued liabilities | 449 | 911 | 105 | |||
| Debt | 2,644 | |||||
| Due to related parties | ✕ | ✕ | 25 | 2 | ||
| Other undisclosed current liabilities | 1,828 | |||||
| Total current liabilities: | 4,921 | 936 | 107 | |||
| Noncurrent Liabilities | ||||||
| Liabilities, other than long-term debt | 14 | 37 | 7,216 | |||
| Deferred income tax liabilities | 14 | |||||
| Derivative instruments and hedges, liabilities | 37 | 7,216 | ||||
| Other undisclosed noncurrent liabilities | 157 | 858 | ||||
| Total noncurrent liabilities: | 170 | 895 | 7,216 | |||
| Total liabilities: | 5,092 | 1,830 | 7,323 | |||
| Temporary equity, carrying amount | 9,252 | 193,525 | 191,648 | |||
| Equity | ||||||
| Equity, attributable to parent | (3,459) | (619) | (5,909) | |||
| Common stock | 1 | 1 | 1 | |||
| Accumulated deficit | (3,460) | (620) | (5,910) | |||
| Total equity: | (3,459) | (619) | (5,909) | |||
| TOTAL LIABILITIES AND EQUITY: | 10,885 | 194,736 | 193,061 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Revenues | 1,192 | 8,938 | |||
| Net investment income | 1,192 | 8,938 | |||
| Cost of revenue (Cost of Goods and Services Sold) | |||||
| Gross profit: | 1,192 | 8,938 | |||
| Operating expenses | (1,509) | (1,271) | |||
| Other undisclosed operating loss | (1,192) | (8,938) | |||
| Operating loss: | (1,509) | (1,271) | |||
| Nonoperating income | 3,127 | 2,579 | |||
| Investment income, nonoperating | 2,249 | 2,579 | |||
| Income (loss) from continuing operations before equity method investments, income taxes: | 1,619 | 1,309 | |||
| Other undisclosed income from continuing operations before income taxes | 6,358 | ||||
| Income (loss) from continuing operations before income taxes: | 1,619 | 7,667 | |||
| Income tax expense | (457) | (499) | |||
| Net income (loss) attributable to parent: | 1,162 | 7,168 | |||
| Preferred stock dividends and other adjustments | (2,138) | (193,525) | |||
| Net loss available to common stockholders, diluted: | (976) | (186,358) | |||
Comprehensive Income ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Net income (loss): | 1,162 | 7,168 | |||
| Comprehensive income (loss), net of tax, attributable to parent: | 1,162 | 7,168 | |||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.